Psilocybin fungi, aka "magic" mushrooms, are well known for inducing colorful and visionary states of mind. Such psychoactive properties and the ease of cultivating their basidiocarps within low-tech setups make psilocybin fungi promising pharmacological tools for mental health applications. Understanding of the intrinsic electrical patterns occurring during the mycelial growth can be utilized...
Abstract Psychedelics are a unique class of drug that commonly produce vivid hallucinations as well as profound psychological and mystical experiences. A grouping of interconnected brain regions characterized by increased temporal coherence at rest have been termed the Default Mode Network (DMN). The DMN has been the focus of numerous studies assessing its role in self-referencing, mind...
Microdosing is the practice of regularly using very low doses of psychedelic drugs. Anecdotal reports suggest that it may enhance well-being, creativity and cognition. Here, we use data from a self-blinding microdose trial, a large (n=240) placebo-controlled citizen science trial of microdosing to investigate whether tolerance develops during microdosing. We conceptualized tolerance as the...
Departments of Psychiatry and Behavioral Neurosciences and Anesthesiology, Wayne State University, Detroit, MI [email protected] Received August 19, 2022; accepted after revision August 29, 2022. The author declares no conflicts of interest. There was no funding provided for this work. A podcast discussing this article is available online at the journal website.
Classic psychedelics, such as psilocybin and LSD, and other serotonin 2A receptor (5-HT2AR) agonists evoke acute alterations in perception and cognition. Altered thalamocortical connectivity has been hypothesized to underlie these effects, which is supported by some functional MRI (fMRI) studies. These studies have treated the thalamus as a unitary structure, despite known differential 5-HT2AR...
The beneficial effects of psilocybin‐assisted psychotherapy on alcohol use disorder (AUD) are significant, based on a study published in JAMA Psychiatry last month. In general, psychedelic medications have been a focus of research, but less is known about psilocybin, and it has been 40 years since the studies with lysergic acid diethylamide (LSD) provided double the remissions as comparison...
The pharmacological mechanisms of mescaline are similar to those of other classical psychedelics, like psilocybin and lysergic acid diethylamide (LSD). Mescaline appears to be safe to consume, with most intoxications being mild and easily treatable. Improvement in mental well-being and its ability to overcome alcoholism render mescaline potentially beneficial in clinical settings. This article...
Following a decades long period of investigational dormancy, there is renewed interest in employing psychedelics as psychiatric treatments. The academic journals, institutions, and countries that have helped sustain clinical psychedelic research and the evolution of the literature on clinical studies of psychedelics have only recently begun to be investigated. To expand upon this work, we...
Therapy is turning to drugs previously known for being illicit party substances. But there’s no reason to abandon proper trials. A range of new therapies for mental illness were previously considered unthinkable — party drugs including ketamine, medicinal cannabis and psychedelics like MDMA, psilocybin and DMT. With mental health disorders a growing cause of disability […]
Sixty healthy volunteers took magic mushrooms in a lab, and scientists recorded their brains during their experience. Approximately half of the Australian population will experience a mental health disorder during their lifetime, and scientists are turning to an unlikely place in the search for treatment. Researchers at Monash University are scanning the brains of healthy […]
Certain species of the mushrooms contain the Indole Alkaloids such as Psilocybin and Psilocin which exhibit the psychedelic property. These types of mushrooms can be identified by their unique property known as the blue bruising. These alkaloid compounds may cause the hallucinations and other symptoms. The psilocybin and Psilocin are synthesized from the amino acid Tryptophan and resemble the...
Psychedelic compounds have been linked to salutary mental health outcomes in both naturalistic and clinical settings; however, current research on psychedelics suffers from a lack of inclusion and focus on racial and ethnic minorities. Thus, the goal of our study was to assess whether race and ethnicity moderate the associations that naturalistic lifetime MDMA...
Giving lab rats illicit psychedelic drugs may help scientists uncover how it can be used to treat anorexia in humans. Psychedelics, including psilocybin — the psychoactive compound produced by ‘magic mushrooms’ — show promise in treating the eating disorder anorexia nervosa. But they don’t work for everyone. Anorexia nervosa is a mental health disorder that […]
As a flurry of US states approve psilocybin for medicinal use, Joanne Silberner asks whether the most carefully studied of psychedelic drugs will revolutionise treatment of depression and other psychiatric ailments
The Yale Program for Psychedelic Science (YPPS) is testing the safety and efficacy of psilocybin, administered in conjunction with non-directive psychological support, as a treatment for certain neurological and psychiatric conditions. The study, HIC: 200020355 (Neural correlates of the effects of psilocybin in obsessive-compulsive disorder: A double-blind, placebo-controlled study), will...
Research on the therapeutic potential of psychedelic substances is expanding. A limitation within this field is the unpredictability of individual responses to psychedelics. Better understanding of factors predicting psychedelic experience is essential to clinical progress and wider harm reduction frameworks. Ketamine, MDMA, LSD and psilocybin were selected for comparison due to their promising...
Background Psilocybin-induced mystical-type experiences are associated with lasting positive psychological outcomes. Recent studies indicate that trait mindfulness is increased 3 months after psilocybin intake, preceded by decreases in neocortical serotonin 2A receptor (5-HT 2A R) binding. However, the association between psilocybin-induced mystical-type experiences and subsequent changes in...
Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck...
ChemistrySelectOctober 4, 2022Poonam Bhadoria, V. Ramanathan5 citations
Abstract The conformational manifold of psilocybin, a psychedelic molecule, was extensively explored using DFT method. Two most stable conformers were identified and the second most stable conformer was found to be 2.08 kcal/mol higher than the global minimum. The barrier of rotation between the two conformers was found to be 14.63 kcal/mol. The structural and spectroscopic parameters of both...
Psychedelics including lysergic acid diethylamide (LSD) and psilocybin temporarily alter subjective experience through their neurochemical effects. Serotonin 2a (5-HT2a) receptor agonism by these compounds is associated with more diverse (entropic) brain activity. We postulate that this increase in entropy may arise in part from a flattening of the brain's control energy landscape, which can be...